David G. Pfister

36.2k total citations · 9 hit papers
328 papers, 19.3k citations indexed

About

David G. Pfister is a scholar working on Oncology, Otorhinolaryngology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David G. Pfister has authored 328 papers receiving a total of 19.3k indexed citations (citations by other indexed papers that have themselves been cited), including 147 papers in Oncology, 145 papers in Otorhinolaryngology and 114 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David G. Pfister's work include Head and Neck Cancer Studies (144 papers), Head and Neck Surgical Oncology (48 papers) and Lung Cancer Treatments and Mutations (43 papers). David G. Pfister is often cited by papers focused on Head and Neck Cancer Studies (144 papers), Head and Neck Surgical Oncology (48 papers) and Lung Cancer Treatments and Mutations (43 papers). David G. Pfister collaborates with scholars based in United States, Germany and Switzerland. David G. Pfister's co-authors include Dennis H. Kraus, Jatin P. Shah, Nancy Y. Lee, Eric J. Sherman, Suzanne L. Wolden, Michael J. Zeléfsky, Matthew G. Fury, Mark R. Somerfield, Ashok R. Shaha and Alan L. Ho and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

David G. Pfister

312 papers receiving 18.8k citations

Hit Papers

American Society of Clinical Oncology Treatment of Unrese... 1999 2026 2008 2017 2003 2009 2001 2000 2013 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
    2003 1.2k citations David G. Pfister, David H. Johnson et al. Journal of Clinical Oncology profile →
  2. American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
    2009 752 citations Christopher G. Azzoli, Sherman Baker et al. Journal of Clinical Oncology profile →
  3. Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology*
    2001 616 citations David G. Pfister et al. Journal of Clinical Oncology profile →
  4. Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin
    2000 596 citations David G. Pfister et al. Journal of Clinical Oncology profile →
  5. Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
    2013 555 citations Alan L. Ho, Eric J. Sherman et al. profile →
  6. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
    2017 497 citations Joshua Bauml, Tanguy Y. Seiwert et al. Journal of Clinical Oncology profile →
  7. Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
    1999 483 citations David G. Pfister et al. Journal of Clinical Oncology profile →
  8. Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
    2011 445 citations David G. Pfister, Robert F. Gagel et al. Journal of Clinical Oncology profile →
  9. Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma
    2020 264 citations Sean M. McBride, Eric J. Sherman et al. Journal of Clinical Oncology profile →

Peers

David G. Pfister
M. Bolla France
Roger A’Hern United Kingdom
Jong‐Lyel Roh South Korea
Andrew K. Stewart United States
Johannes A. Langendijk Netherlands
Mitchell Machtay United States
Andrea Bezjak Canada
Benjamin D. Smith United States
Gregory R. Pond Canada
Ben J. Slotman Netherlands
M. Bolla France
David G. Pfister
Citations per year, relative to David G. Pfister David G. Pfister (= 1×) peers M. Bolla

Countries citing papers authored by David G. Pfister

Since Specialization
Citations

This map shows the geographic impact of David G. Pfister's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David G. Pfister with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David G. Pfister more than expected).

Fields of papers citing papers by David G. Pfister

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David G. Pfister. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David G. Pfister. The network helps show where David G. Pfister may publish in the future.

Co-authorship network of co-authors of David G. Pfister

This figure shows the co-authorship network connecting the top 25 collaborators of David G. Pfister. A scholar is included among the top collaborators of David G. Pfister based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David G. Pfister. David G. Pfister is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Raab, Gabriel, Bin Xu, Nora Katabi, et al.. (2025). Pathologic Response to Neoadjuvant Cetuximab, Platinum, and Taxane in Locally Advanced HNSCC. Otolaryngology. 174(1). 163–172.
2.
Brandenstein, Melanie von, David G. Pfister, Pia Paffenholz, et al.. (2025). Expression and therapeutic potential of TROP2 in cisplatin-resistant germ cell tumors. Journal of Cancer Research and Clinical Oncology. 151(11). 279–279.
3.
Cracchiolo, Jennifer R., Richard J. Wong, Alan L. Ho, et al.. (2025). Defining response-adapted surgery after neoadjuvant therapy in oral cavity cancer. Oral Oncology. 165. 107349–107349. 2 indexed citations
4.
Dunn, Lara, Alan L. Ho, & David G. Pfister. (2025). Head and Neck Cancer. JAMA. 335(6). 531–531.
5.
Desîlets, Antoine, David G. Pfister, Sarah Stein, et al.. (2024). A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer. Oral Oncology. 154. 106861–106861. 4 indexed citations
6.
Woods, Robbie, Conall Fitzgerald, Dauren Adilbay, et al.. (2024). Outcomes of SMARCB1‐deficient sinonasal carcinoma: Largest single‐center cross‐sectional study. Head & Neck. 46(12). 3076–3084. 1 indexed citations
7.
Razak, Albiruni Ryan Abdul, Hung‐Ming Wang, Jang‐Yang Chang, et al.. (2023). A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Targeted Oncology. 18(6). 853–868. 10 indexed citations
8.
Nabell, Lisle M., Alan L. Ho, Marshall R. Posner, et al.. (2023). 921P HB-200 arenavirus-based immunotherapy plus pembrolizumab as a first-line treatment of patients with recurrent/metastatic HPV16 positive head and neck cancer. Annals of Oncology. 34. S581–S582. 3 indexed citations
9.
Gelblum, Daphna Y., et al.. (2023). Virtual Tumor Board to Foster Interinstitutional Head and Neck Cancer Subspecialty Care. JAMA Otolaryngology–Head & Neck Surgery. 149(12). 1153–1153.
10.
Desîlets, Antoine, David G. Pfister, Winston Wong, et al.. (2023). A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer.. Journal of Clinical Oncology. 41(16_suppl). 6025–6025. 2 indexed citations
11.
Ho, Alan L., Nathan R. Foster, Shyamprasad Deraje Vasudeva, et al.. (2023). A phase 2 study of MK‐2206 in patients with incurable adenoid cystic carcinoma (Alliance A091104). Cancer. 130(5). 702–712. 5 indexed citations
12.
13.
McBride, Sean M., Eric J. Sherman, C. Jillian Tsai, et al.. (2020). Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. Journal of Clinical Oncology. 39(1). 30–37. 264 indexed citations breakdown →
14.
Cohen, Marc A., David G. Pfister, Nancy Y. Lee, et al.. (2020). Case study of the integration of electronic patient‐reported outcomes as standard of care in a head and neck oncology practice: Obstacles and opportunities. Cancer. 127(3). 359–371. 12 indexed citations
15.
Cracchiolo, Jennifer R., Bin Xu, Jocelyn Migliacci, et al.. (2018). Patterns of recurrence in oral tongue cancer with perineural invasion. Head & Neck. 40(6). 1287–1295. 64 indexed citations
16.
Bauml, Joshua, Tanguy Y. Seiwert, David G. Pfister, et al.. (2017). Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. Journal of Clinical Oncology. 35(14). 1542–1549. 497 indexed citations breakdown →
17.
Roman, Benjamin R., Shrujal S. Baxi, Jennifer R. Cracchiolo, et al.. (2017). Variation in use of postoperative chemoradiation following surgery for T1 and T2 oropharyngeal squamous cell carcinoma; National Cancer Database. Journal of Surgical Oncology. 116(3). 351–358. 6 indexed citations
18.
Wells, Samuel A., Jessica E. Gosnell, Robert F. Gagel, et al.. (2010). Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer. Journal of Clinical Oncology. 28(5). 767–772. 380 indexed citations
19.
Setton, Jeremy, N. Caria, Jonathan Romanyshyn, et al.. (2010). Intensity-Modulated Radiotherapy in the Treatment of Oropharyngeal Cancer: An Update of the Memorial Sloan-Kettering Cancer Center Experience. International Journal of Radiation Oncology*Biology*Physics. 82(1). 291–298. 136 indexed citations
20.
Azzoli, Christopher G., Sherman Baker, Sarah Temin, et al.. (2009). American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 27(36). 6251–6266. 752 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. Bolla Breakdown of academic impact, for papers by Roger A’Hern Breakdown of academic impact, for papers by Jong‐Lyel Roh Breakdown of academic impact, for papers by Andrew K. Stewart Breakdown of academic impact, for papers by Johannes A. Langendijk Breakdown of academic impact, for papers by Mitchell Machtay Breakdown of academic impact, for papers by Andrea Bezjak Breakdown of academic impact, for papers by Benjamin D. Smith Breakdown of academic impact, for papers by Gregory R. Pond Breakdown of academic impact, for papers by Ben J. Slotman
Rankless by CCL
2026